LCTX RSI Chart
Last 7 days
-15.0%
Last 30 days
-3.1%
Last 90 days
10.6%
Trailing 12 Months
-11.3%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 11.9M | 10.5M | 8.8M | 8.9M |
2022 | 5.6M | 10.1M | 13.0M | 14.7M |
2021 | 666.0K | 684.0K | 751.0K | 445.0K |
2020 | 678.0K | 0 | 0 | 0 |
2019 | 545.0K | 322.0K | 256.0K | 257.0K |
2018 | 2.3M | 2.3M | 691.0K | 691.0K |
2017 | 4.9M | 3.8M | 2.8M | 1.8M |
2016 | 7.0M | 6.5M | 6.1M | 5.9M |
2015 | 4.5M | 5.4M | 6.3M | 5.9M |
2014 | 4.1M | 4.0M | 4.4M | 4.4M |
2013 | 3.3M | 3.4M | 3.0M | 3.6M |
2012 | 4.2M | 4.4M | 4.0M | 3.5M |
2011 | 3.8M | 3.8M | 4.2M | 4.4M |
2010 | 0 | 2.5M | 3.1M | 3.7M |
2009 | 0 | 0 | 0 | 1.9M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 11, 2024 | samuel george a. iii | acquired | - | - | 6,076 | general counsel/secretary |
Feb 11, 2024 | samuel george a. iii | sold (taxes) | -2,689 | 1.08 | -2,490 | general counsel/secretary |
Feb 11, 2024 | culley brian m | sold (taxes) | -13,830 | 1.08 | -12,806 | president and ceo |
Feb 11, 2024 | culley brian m | acquired | - | - | 31,249 | president and ceo |
Feb 08, 2024 | bailey don m | bought | 100,001 | 1.04 | 96,155 | - |
Feb 06, 2024 | broadwood partners, l.p. | bought | - | - | - | - |
Feb 06, 2024 | broadwood partners, l.p. | bought | 7,000,000 | 1.04 | 6,730,770 | - |
Dec 29, 2023 | jayasuriya anula | bought | 10,900 | 1.09 | 10,000 | - |
Feb 11, 2023 | culley brian m | acquired | - | - | 31,249 | president and ceo |
Feb 11, 2023 | samuel george a. iii | sold (taxes) | -3,345 | 1.35 | -2,478 | general counsel/secretary |
Which funds bought or sold LCTX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 12, 2024 | Pacifica Partners Inc. | unchanged | - | 787 | 3,713 | -% |
Apr 10, 2024 | Founders Capital Management | unchanged | - | 3,120 | 11,840 | 0.01% |
Apr 05, 2024 | CWM, LLC | new | - | 2,000 | 2,000 | -% |
Apr 04, 2024 | TRUST CO OF TOLEDO NA /OH/ | unchanged | - | 13,180 | 50,017 | 0.01% |
Apr 02, 2024 | ST GERMAIN D J CO INC | unchanged | - | 1.00 | 3.00 | -% |
Mar 28, 2024 | Newbridge Financial Services Group, Inc. | unchanged | - | -1.00 | 5.00 | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 196 | 196 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 0.87 | -669,243 | 9,139,310 | -% |
Mar 05, 2024 | Fisher Asset Management, LLC | new | - | 10,900 | 10,900 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 150 | 46,364 | 81,634 | -% |
Unveiling Lineage Cell Therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Lineage Cell Therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.7B | 6.8B | -8.42 | 5.79 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.6B | 1.8B | -42.25 | 10.17 | ||||
BMRN | 17.3B | 2.4B | 103 | 7.14 | ||||
INCY | 12.0B | 3.7B | 20.07 | 3.25 | ||||
MID-CAP | ||||||||
APLS | 6.2B | 396.6M | -11.74 | 15.65 | ||||
BBIO | 4.5B | - | -6.94 | 60.35 | ||||
AXSM | 3.2B | 270.6M | -13.52 | 11.95 | ||||
ARWR | 3.0B | 240.7M | -10.03 | 12.36 | ||||
ACAD | 2.8B | 726.4M | -45.41 | 3.83 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.42 | 4.56 | ||||
NVAX | 576.6M | 983.7M | -1.06 | 0.59 | ||||
CRBP | 448.6M | 881.7K | -10.06 | 466.16 | ||||
INO | 256.8M | 4.9M | -1.9 | 52.78 | ||||
IBIO | 6.7M | 2.1M | -0.25 | 2.14 |
Lineage Cell Therapeutics Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
Revenue | 67.6% | 2,088,000 | 1,246,000 | 3,225,000 | 2,386,000 | 1,915,000 | 2,998,000 | 4,553,000 | 5,237,000 | 208,000 | 68,000 | 71,000 | 98,000 | 514,000 | 1,000 | 53,000 | 110,000 | 93,000 | - | 119,000 | 333,000 | 239,000 |
Cost Of Revenue | 51.5% | 256,000 | 169,000 | 127,000 | 119,000 | 102,000 | 235,000 | 215,000 | 176,000 | 204,000 | 985,000 | 125,000 | 112,000 | 94,000 | 123,000 | 114,000 | 107,000 | 68,000 | 52,000 | 35,000 | 106,000 | 109,000 |
Gross Profit | 70.1% | 1,832,000 | 1,077,000 | 3,098,000 | 2,267,000 | 1,813,000 | 2,763,000 | 4,338,000 | 5,061,000 | 964,000 | 1,285,000 | 387,000 | 279,000 | 420,000 | 1,118,000 | 453,000 | 672,000 | 860,000 | 706,000 | 947,000 | 2,441,000 | 592,000 |
Operating Expenses | 5.3% | 8,194,000 | 7,782,000 | 8,122,000 | 8,909,000 | 8,452,000 | 8,014,000 | 8,572,000 | 11,457,000 | 29,202,000 | 8,128,000 | 7,467,000 | 7,329,000 | 7,858,000 | 7,990,000 | 8,875,000 | 11,493,000 | 13,621,000 | 10,813,000 | 11,304,000 | 11,585,000 | 12,779,000 |
S&GA Expenses | 6.1% | 4,288,000 | 4,041,000 | 4,249,000 | 4,724,000 | 4,347,500 | 4,422,000 | 5,270,000 | 8,469,000 | 4,424,000 | 5,317,000 | 4,536,000 | 3,935,000 | 4,519,000 | 4,504,000 | 4,609,000 | 6,258,000 | 8,660,000 | 7,087,000 | 6,422,000 | 5,227,000 | 6,044,000 |
R&D Expenses | 4.4% | 3,906,000 | 3,741,000 | 3,873,000 | 4,185,000 | 4,104,500 | 3,592,000 | 3,302,000 | 2,988,000 | 24,778,000 | 2,811,000 | 2,931,000 | 3,394,000 | 3,339,000 | 3,486,000 | 4,266,000 | 5,235,000 | 4,961,000 | 3,780,000 | 4,882,000 | 6,358,000 | 5,935,000 |
EBITDA Margin | 9.0% | -2.36 | -2.59 | -2.02 | -1.95 | -1.66 | -3.57 | -4.97 | -8.64 | -95.74 | -18.07 | -18.11 | -20.31 | - | - | - | - | - | - | - | - | - |
Interest Expenses | -100.0% | - | 433,000 | 382,000 | 410,000 | 393,500 | 384,000 | 51,000 | 1,000 | 2,500 | 1,000 | -3,000 | 2,000 | - | - | - | - | - | - | - | - | - |
Income Taxes | - | - | - | - | - | 41,000 | 541,000 | - | - | - | -1,012,000 | - | - | - | - | - | - | 4,384,000 | 5,520,977 | - | - | - |
Earnings Before Taxes | 34.1% | -4,714,000 | -7,158,000 | -5,203,000 | -6,207,000 | -6,362,000 | -5,575,000 | -6,782,000 | -7,093,000 | -28,010,000 | -8,846,000 | -4,965,000 | -1,448,000 | -8,428,000 | -5,340,000 | -17,506,000 | -31,300,000 | 34,912,000 | -45,330,000 | 66,544,000 | -4,646,000 | -63,698,000 |
EBT Margin | 8.4% | -2.60 | -2.84 | -2.22 | -2.10 | -1.76 | -3.65 | -5.04 | -8.76 | -97.23 | -19.01 | -19.56 | -22.44 | - | - | - | - | - | - | - | - | - |
Net Income | 32.8% | -4,775,000 | -7,110,000 | -5,203,000 | -4,404,000 | -6,354,000 | -6,069,000 | -6,782,000 | -7,093,000 | -28,992,000 | -7,823,000 | -4,788,000 | -1,416,000 | -8,399,000 | -4,482,000 | -16,505,000 | -30,032,000 | 39,310,000 | -44,952,000 | 66,725,000 | -4,215,000 | -63,548,000 |
Net Income Margin | 8.6% | -2.40 | -2.63 | -2.09 | -1.99 | -1.79 | -3.77 | -5.04 | -8.72 | -96.67 | -15.97 | -17.44 | -20.52 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -18.0% | -6,110,000 | -5,176,000 | -6,524,000 | -11,430,000 | -8,287,000 | -5,766,000 | -7,159,000 | 21,858,000 | -6,019,000 | -4,902,000 | -5,545,000 | -7,435,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -4.8% | 101 | 106 | 112 | 113 | 124 | 131 | 136 | 145 | 175 | 131 | 135 | 128 | 108 | 103 | 112 | 119 | 125 | 133 | 152 | 184 | 102 |
Current Assets | -11.6% | 38.00 | 43.00 | 48.00 | 50.00 | 60.00 | 69.00 | 74.00 | 82.00 | 112 | 68.00 | 72.00 | 65.00 | 44.00 | 40.00 | 46.00 | 52.00 | 58.00 | 62.00 | 20.00 | 31.00 | 36.00 |
Cash Equivalents | 12.6% | 35.00 | 31.00 | 34.00 | 15.00 | 11.00 | 25.00 | 71.00 | 78.00 | 56.00 | 61.00 | 62.00 | 56.00 | 33.00 | 33.00 | 13.00 | 10.00 | 9.00 | 14.00 | 8.00 | 18.00 | 24.00 |
Net PPE | -1.8% | 5.00 | 5.00 | 5.00 | 6.00 | 6.00 | 5.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 5.00 | 7.00 | 8.00 | 8.00 | 9.00 | 9.00 | 9.00 | 6.00 |
Goodwill | 0% | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 13.00 | 13.00 | 13.00 | - |
Liabilities | -1.3% | 39.00 | 39.00 | 40.00 | 44.00 | 52.00 | 54.00 | 54.00 | 59.00 | 84.00 | 12.00 | 11.00 | 11.00 | 13.00 | 13.00 | 14.00 | 14.00 | 14.00 | 17.00 | 20.00 | 22.00 | 9.00 |
Current Liabilities | 13.1% | 18.00 | 16.00 | 16.00 | 17.00 | 19.00 | 23.00 | 25.00 | 25.00 | 47.00 | 9.00 | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 7.00 | 6.00 | 6.00 | 8.00 | 9.00 | 7.00 |
Shareholder's Equity | -8.9% | 62.00 | 68.00 | 71.00 | 69.00 | 73.00 | 78.00 | 81.00 | 85.00 | 91.00 | 120 | 124 | 117 | 95.00 | 90.00 | 98.00 | 105 | 111 | 116 | 132 | 161 | 92.00 |
Retained Earnings | -1.3% | -384 | -380 | -372 | -367 | -363 | -357 | -350 | -344 | -337 | -308 | -300 | -295 | -294 | -296 | -288 | -281 | -273 | -268 | -252 | -222 | -261 |
Shares Outstanding | 0% | 175 | 175 | 174 | 170 | 170 | 170 | 170 | 170 | 169 | 163 | 161 | 162 | - | - | - | - | - | - | - | - | - |
Minority Interest | 4.2% | -1.40 | -1.46 | -1.41 | -1.43 | -1.40 | -1.39 | -1.35 | -1.33 | -1.32 | -1.12 | -1.11 | -1.10 | -1.07 | -1.08 | -1.75 | -1.74 | -1.71 | -1.64 | -1.63 | -1.61 | -1.59 |
Float | - | - | - | - | - | - | - | 201 | - | - | - | 357 | - | - | - | 94.00 | - | - | - | 119 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -19.5% | -6,019 | -5,037 | -6,268 | -11,242 | -8,303 | -5,480 | -7,062 | 21,904 | -5,873 | -4,848 | -5,416 | -7,424 | -5,641 | -4,847 | -4,239 | -5,026 | -5,523 | -7,443 | -9,667 | -9,314 | -5,812 |
Share Based Compensation | -16.5% | 1,060 | 1,269 | 1,280 | 1,031 | 959 | 987 | 1,235 | 1,106 | 918 | 1,144 | 919 | 539 | 494 | 501 | 606 | 626 | 619 | 759 | 762 | 1,440 | 2,005 |
Cashflow From Investing | 359.1% | 9,742 | 2,122 | 19,159 | 15,426 | -5,102 | -40,914 | -97.00 | -46.00 | -146 | -68.00 | -115 | 10,074 | 902 | 178 | 6,702 | 5,256 | 720 | 13,485 | -194 | 2,946 | 9,784 |
Cashflow From Financing | -101.6% | -13.00 | 807 | 5,628 | 1.00 | 122 | 964 | 33.00 | 513 | 954 | 3,719 | 11,294 | 20,963 | 4,814 | 24,558 | 503 | -10.00 | -5.00 | 79.00 | -63.00 | 606 | 94.00 |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenues [Abstract] | ||
Total revenues | $ 8,945 | $ 14,703 |
Cost of sales | (671) | (728) |
Gross profit | 8,274 | 13,975 |
OPERATING EXPENSES: | ||
Research and development | 15,705 | 13,987 |
General and administrative | 17,302 | 22,508 |
Total operating expenses | 33,007 | 36,495 |
Loss from operations | (24,733) | (22,520) |
OTHER INCOME (EXPENSES): | ||
Interest income, net | 1,629 | 829 |
Loss on marketable equity securities, net | (176) | (2,194) |
Gain on revaluation of warrant liability | 2 | 225 |
Other expenses, net | (4) | (2,152) |
Total other income (expenses), net | 1,451 | (3,292) |
Loss before net income tax benefit | (23,282) | (25,812) |
Provision for income tax benefit (expense) | 1,803 | (541) |
Net loss | (21,479) | (26,353) |
Net (income) loss attributable to noncontrolling interest | (7) | 80 |
NET LOSS ATTRIBUTABLE TO LINEAGE CELL THERAPEUTICS, INC. | $ (21,486) | $ (26,273) |
NET LOSS ATTRIBUTABLE TO LINEAGE | ||
Basic | $ (0.12) | $ (0.15) |
Diluted | $ (0.12) | $ (0.15) |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | ||
Basic | 172,663 | 169,792 |
Diluted | 172,663 | 169,792 |
Collaboration Revenues [Member] | ||
Revenues [Abstract] | ||
Total revenues | $ 7,588 | $ 13,367 |
Royalties, License and Other Revenues [Member] | ||
Revenues [Abstract] | ||
Total revenues | $ 1,357 | $ 1,336 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 | ||
---|---|---|---|---|
CURRENT ASSETS | ||||
Cash and cash equivalents | $ 35,442 | $ 11,355 | ||
Marketable securities | 50 | 46,520 | ||
Accounts receivable, net (Note 3) | 745 | 297 | ||
Prepaid expenses and other current assets | 2,204 | 1,828 | ||
Total current assets | 38,441 | 60,000 | ||
NONCURRENT ASSETS | ||||
Property and equipment, net (Notes 6 and 14) | 4,767 | 5,673 | ||
Deposits and other long-term assets | 577 | 627 | ||
Goodwill | [1] | 10,672 | 10,672 | |
Intangible assets, net | 46,562 | 46,692 | ||
TOTAL ASSETS | 101,019 | 123,664 | ||
CURRENT LIABILITIES | ||||
Accounts payable and accrued liabilities | 6,270 | 8,608 | ||
Operating lease liabilities, current portion (Note 14) | 830 | 916 | ||
Finance lease liabilities, current portion (Note 14) | 52 | 36 | ||
Deferred revenues, current portion (Note 3) | 10,808 | 9,421 | ||
Total current liabilities | 17,960 | 18,981 | ||
LONG-TERM LIABILITIES | ||||
Deferred tax liability (Note 13) | 273 | 2,076 | ||
Deferred revenues, net of current portion (Note 3) | 18,693 | 27,725 | ||
Operating lease liabilities, net of current portion (Note 14) | 1,979 | 2,860 | ||
Finance lease liabilities, net of current portion (Note 14) | 91 | 84 | ||
Other long-term liabilities | 0 | 2 | ||
TOTAL LIABILITIES | 38,996 | 51,728 | ||
Commitments and contingencies (Note 14) | ||||
SHAREHOLDERS' EQUITY | ||||
Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of December 31, 2023 and 2022 | ||||
Common shares, no par value, 450,000 and 250,000 shares authorized as of December 31, 2023 and 2022, respectively; 174,987 and 170,093 shares issued and outstanding as of December 31, 2023 and 2022, respectively | 451,343 | 440,280 | ||
Accumulated other comprehensive loss | (3,068) | (3,571) | ||
Accumulated deficit | (384,856) | (363,370) | ||
Lineage's shareholders' equity | 63,419 | 73,339 | ||
Noncontrolling deficit | (1,396) | (1,403) | ||
Total shareholders’ equity | 62,023 | 71,936 | ||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ 101,019 | $ 123,664 | ||
|